Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news


From To
The deadly toll of drug-approval drag

A recent survey of general practitioners by the Canadian Liver Foundation revealed 57 per cent of GPs don't know hepatitis C can be cured despite the fact more than 70 per cent of hep C patients who undergo treatment with available medicines are being cured right now.

14 February 2014
Winnipeg Free Press
Gilead's CEO Says New Hepatitis C Drug Attracts Payers

Gilead Sciences Inc. (GILD:US), the world’s largest maker of HIV medicines, said insurers have responded favorably over coverage of its new hepatitis C drug, which has a price tag of $84,000 for a 12-week course of treatment.

13 February 2014
Bloomberg Businessweek
Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Hepatitis C

The data submitted in the NDA support the use of LDV/SOF in patients with genotype 1 hepatitis C virus (HCV) infection, with a treatment duration of eight or 12 weeks depending on prior treatment history and whether they have cirrhosis. Approximately 75 percent of people infected with HCV in the United States have the genotype 1 strain of the virus.

11 February 2014
Gilead press release
New hepatitis C pill lifts Gilead's 4Q sales

Gilead Sciences said Tuesday that sales of its hepatitis C pill Sovaldi totaled $139.4 million after the drug was approved in December, helping its fourth-quarter profit rise 4 percent.

07 February 2014
Bloomberg Businessweek
Gilead to license hepatitis C drug to lower-cost manufacturers in India

Gilead Sciences plans to license its breakthrough hepatitis C drug Sovaldi to a number of Indian generic pharmaceutical manufacturers, allowing for lower-priced sales of the medication in that developing nation, according to the company.

06 February 2014
Gilead, local generic players in talks to bring hepatitis C drug into India

California-based drug-maker Gilead Sciences Inc is in discussions with a handful of local pharmaceutical companies to bring its much anticipated oral Hepatitis C drug Sovaldi (sofosbuvir) into India.

04 February 2014
The Hindu
Abbvie Strong Hep C Drug Data and the Looming Battle With Gilead Sciences

The hepatitis C drug-marketing battle is heating up. Both the Abbvie and Gilead hepatitis C regimens are equally effective, with SVR (cure) rates in the high 90% range for both treatment naive and experienced patients. That means the choice for doctors and patients will likely come down to convenience and price.

03 February 2014
The Street
AbbVie Completes Largest Phase III Program of an All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C Genotype 1

AbbVie has completed phase III studies of its interferon-free three-drug regimen and reports SVR(12) rates above 90% in all patients groups studied, including 92%-96% SVR(12) rates in patients with compensated cirrhosis. AbbVie expects a 2014 US launch.

31 January 2014
AbbVie press release
US medical societies launch new hepatitis C treatment guidelines

The American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA) and International Antiviral Society-USA (IAS-USA) yesterday announced the first

30 January 2014
Liz Highleyman
At $84000 Gilead Hepatitis C Drug Sets Off Payer Revolt

Gilead’s new drug, Sovaldi, costs $84,000 for a 12-week treatment. Such breakthrough treatments and their stratospheric price tags have “absolutely” caused insurers to reconsider covering high-priced hepatitis, diabetes and other treatments, said Sumit Dutta, chief medical officer of Catamaran, the fourth-biggest U.S. pharmacy benefit manager, or PBM.

27 January 2014

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.